Ascelia Pharma: On the way to submission with secured capital to engage in partner discussions - Redeye

Ascelia’s actual 21 result is minor compared with the recent SPARKLE success and the ongoing SEK 105m funding where SEK 70m is secured. Ascelia is preparing for submission by mid-2025, and Ascelia’s cost base is contained. Our recent Base Case is SEK 17 (Bull SEK 45 and Bear SEK 6). Ascelia has a very undemanding valuation, even after considering the potential dilution from the ongoing rights issue, priced at SEK 1.69 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/1030097/ascelia-pharma-on-the-way-to-submission-with-secured-capital-to-engage-in-partner-discussions?utm_source=finwire&utm_medium=RSS